Life Science Tools and Technologies for Bio-Pharma R&D

Summary

This market research report is about the important market for life science tools & techs that are used for accelerating the research processes and capabilities of biopharmaceutical R&D. This key research information is valuable and offers readers a detailed overview of the size and shape of the life science tools and techs market and what the products can do to facilitate the advancement of pharmaceutical and biotech drug R&D programs.

Significant life science industry information is presented and reviewed. While pharmaceutical industry generated more than $255 billion in 2002, pharma companies are facing many important issues that could be helped by using new life science tools and technologies. A broad range of industry data is analyzed and reveals that pharma companies have seen their R&D costs dramatically increase over the last twenty years, while their product productivity has declined. In addition, many existing and profitable blockbuster drugs will reach patent expiration dates between 2005-2006. This situation will attract competition from generic or other branded drug makers. It shows that there is a clear need driving the desire for more innovation.

For buyers and sellers of life science tools and techs, this report shows that major pharma companies have increasingly become a source of significant strategic alliance opportunities for many of the companies that comprise the US biotechnology industry. Major pharma companies are motivated to become customers and partners of life science tools companies because the many "tools" companies offer technologies that enable them become more productive, reduce bottlenecks and deliver more marketable products, at less cost, and in a shorter time than in the current 10 to 15-year sequential drug development timeline.

Industrialization of pharmaceutical and biotech R&D has begun. These firms are using genomics and proteomics technologies, and other life science tools that can help these companies reach their drug product objectives. The report discusses some of the newest life science tools and tech advancements including nanobiotechnology, rolling circle amplification technology (RCAT), ICAT, RNAi, phage display, yeast 2 hybrid, PROfusion technology, surface plasmon resonance, biochips, protein arrays, separation technologies, 2D PAGE, HPLC, TOF/TOF, drug target discovery and validation tools among others.

This report has found that the life science tools & techs market size in 2002 was about $1.6 billion and is projected to more than double to about $3.5 billion by 2007, growing at a CAGR of 17.7%. While the economy is currently challenging this market, a pickup in growth is expected after 2004. Readers will learn about key business opportunities and the lessons learned from the life science tools and techs companies. This 155-page study uses 34 figures and tables to illustrate the research findings. Participating companies are mapped against multiple technologies to show where they fit in the competitive landscape. Over 27 life science tools & tech companies are profiled, and the report provides insights about the "tools & techs" that these interesting companies offer, including their strategies, funding and so on.

Content